<DOC>
	<DOCNO>NCT00879541</DOCNO>
	<brief_summary>The aim study - ass efficacy Biostate® [ Study Product ( SP ) ] subject Haemophilia A - compare pharmacokinetics Biostate® [ SP ] previously market product Biostate® ( refer Biostate® [ Reference Product ( RP ) ] ) . This study divide 3 part : Part 1 : Cross-over pharmacokinetic ( PK ) component . PK subject randomise determine order receive two study product . This part study double-blinded . Part 2 : Efficacy component . All subject receive Biostate® [ SP ] require manage haemophilia condition estimate period 6 month ( minimum 50 exposure day ) assess efficacy safety product . This part study open-label . Part 3 : Repeat pharmacokinetic assessment . Subjects participate Part 1 ( PK component ) undergo repeat PK assessment Day 180 follow administration Biostate® [ SP ] .</brief_summary>
	<brief_title>Study pd vWF/FVIII , Biostate® , Subjects With Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Diagnosed Haemophilia A ≤ 1 % Factor VIII ( FVIII ) level absence factor replacement Evidence vaccination hepatitis A B ( presence antibody hepatitis A B due either previous infection prior immunisation ) within 10 year prior Day 1 document medical note At least 150 day prior exposure FVIII replacement product Written informed consent give Exclusion Criteria ( participation pharmacokinetic ( PK ) component ) : Active bleeding Body weight &gt; 100 kg Exclusion Criteria ( subject ) : Receipt infusion FVIII product , cryoprecipitate , whole blood , plasma , desmopressin acetate ( DDAVP ) 4 day prior Day 1 Known history FVIII inhibitor , FVIII inhibitor level &gt; 0.6 Bethesda Units ( BU ) screen Receipt aspirin NonSteroidal AntiInflammatory Drugs ( NSAIDs ) within 7 day administration study product . CD4 lymphocytes &lt; 200/µL . Subjects wo HIV1 positive may consider study viral load ≤ 200 particles/µL screen eligibility criterion meet . Impaired liver function ie . bilirubin &gt; 1.5 x upper limit normal ( ULN ) and/or AST/ALT &gt; 2.5 x ULN screen . Acute chronic medical condition , haemophilia A , may , opinion Investigator , affect conduct study von Willebrand Disease ( VWD ) Von Willebrand Factor : Ristocetin Cofactor ( vWF : RCo ) level &lt; 50 IU/dL screen Evidence history ( within previous 12 month ) abuse drug substance , licit illicit Known suspect hypersensitivity previous evidence severe side effect Biostate® , FVIII concentrate human albumin Participation clinical study use investigational compound ( e.g . new chemical entity approve clinical use ) 3 month precede first day study drug administration , plan enter study study period Not willing and/or able comply study requirement</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Hemophilia A</keyword>
</DOC>